Atirmociclib clinical trials
Also written PF-07220060.
How each study uses atirmociclib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the atirmociclib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 0
Pfizer (12) · Olema Pharmaceuticals, Inc. (1) · Hoffmann-La Roche (1) · AstraZeneca (1)
Often tested with
Tested in the same studies.
Vepdegestrant (1) · ORALPF-07220060 (1) · Ipatasertib (1) · SGN-LIV1A (1) · Bevacizumab (1) · Selicrelumab (1) · Tocilizumab (1) · Albumin-Bound Paclitaxel (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test atirmociclib.
Studies
Open first, then newest update. How each study uses atirmociclib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast CancerNot yet recruitingPhase 3PfizerNCT07890597Written as Atirmociclib
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingPhase 2PfizerNCT04557449Written as PF-07220060
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Atirmociclib
- Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerRecruitingPhase 2AstraZenecaNCT07427394Written as Atirmociclib
- A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver DiseaseRecruitingPhase 1PfizerNCT07677358Written as Atirmociclib
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseActive, not recruitingPhase 3PfizerNCT06760637Written as PF-07220060
- A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.Active, not recruitingPhase 1/2PfizerNCT06206837Written as PF-07220060
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruitingPhase 1Olema Pharmaceuticals, Inc.NCT05508906Written as Atirmociclib
- Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy ParticipantsCompletedPhase 1PfizerNCT07215078Written as atirmociclib (PF-07220060)
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentActive, not recruitingPhase 2PfizerNCT06105632Written as PF-07220060 CDK4 inhibitor
- A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post MenopauseCompletedPhase 2PfizerNCT06465368Written as PF-07220060
- A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy ParticipantsCompletedPhase 1PfizerNCT07130097Written as PF-07220060
- A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060CompletedPhase 1PfizerNCT07160738Written as PF-07220060
- A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy AdultsCompletedPhase 1PfizerNCT06267963Written as Oral PF-07220060
- A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060CompletedPhase 1PfizerNCT06897683Written as PF-07220060
Given beside what is tested · 4 — atirmociclib is usual care or a partner of the new treatment
- A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid TumorsNot yet recruitingPhase 1PfizerNCT07897721Written as Atirmociclib
- Study of PF-07248144 in Advanced or Metastatic Solid TumorsRecruitingPhase 2PfizerNCT04606446Written as PF-07220060
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerRecruitingPhase 1Relay Therapeutics, Inc.NCT05216432Written as PF-07220060 100mg
- First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerActive, not recruitingPhase 1OnKure, Inc.NCT06239467Written as Atirmociclib
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered1
Codes
What other systems call atirmociclib · ClinicalTrials.gg INT017864
- UNII (FDA) S743GOJ5LJATIRMOCICLIBConfirmed FDA, Wikidata
- Wikidata Q130633341atirmociclibConfirmed FDA, Wikidata
- NCI Thesaurus C175962AtirmociclibOne source FDA
- DrugBank DB21733One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S743GOJ5LJ | ATIRMOCICLIB | Confirmed FDA, Wikidata |
| Wikidata | Q130633341 | atirmociclib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C175962 | Atirmociclib | One source FDA |
| DrugBank | DB21733 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.